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Background: Mucosally acquired human immunodeficiency virus type 1 (HIV-1) infection results from a limited
number of variants, and these infecting strains potentially have unique properties, such as increased susceptibility
to entry blockers, relative interferon-alpha (IFN-α) resistance, and replication differences in some primary cells. There
is no data about the phenotypic properties of HIV-1 envelope variants found early after acquisition among subjects
infected through injection drug use (IDU). For the first time, we compared the characteristics of virus envelopes
among injection drug users sampled prior to seroconversion (HIV RNA+/Ab-), within 1 year (early), and more than
2 years (chronic) after estimated acquisition.
Results: Virus envelopes from 7 HIV RNA+/Ab- subjects possessed lower genetic diversity and divergence compared
to 7 unrelated individuals sampled during the chronic phase of disease. Replication competent recombinant viruses
incorporating the HIV RNA+/Ab- as compared to the chronic phase envelopes were significantly more sensitive to a
CCR5 receptor inhibitor and IFN-α and showed a statistical trend toward greater sensitivity to a fusion blocker. The early
as compared to chronic infection envelopes also demonstrated a statistical trend or significantly greater sensitivity to
CCR5 and fusion inhibitor and IFN- α. The HIV RNA+/Ab- as compared to chronic envelope viruses replicated to a lower
extent in mature monocyte derived dendritic cells – CD4+ T cell co-cultures, but there were no significant replication
differences in other primary cells among the viruses with envelopes from the 3 different stages of infection.
Conclusions: Similar to mucosal acquisition, HIV-1 envelope quasispecies present in injection drug users prior to
seroconversion have unique phenotypic properties compared to those circulating during the chronic phase of
disease.
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Although injection drug use (IDU) is a relatively common
mode of HIV-1 acquisition, only a small number of studies
have examined genotypic properties of the viruses found
in newly infected subjects who presumably acquired the
infection through IDU [1-4]. Furthermore, phenotypic
characteristics of the viruses circulating in these newly
infected individuals have not been examined in detail.
Transmitted-founder (T/F) or viruses isolated prior to
seroconversion have been most extensively studied in
individuals who acquired their infection through sex-
ual contact [5-14]. There are significant differences in* Correspondence: msagar@bu.edu
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unless otherwise stated.acquiring HIV-1 sexually compared to from IDU. Sexual
acquisition is relatively inefficient potentially because the
virus must cross a mucosal barrier to infect early target
cells at the site of invasion prior to establishing a systemic
infection. On the other hand, the estimated frequency
of transmission is much higher during IDU compared to
the various modes of sexual contact, potentially because
infectious virus often has direct access to bloodstream
susceptible cells [15]. Sexual HIV-1 acquisition is also
associated with a selective bottleneck during transmission
[1,4,6-9,16-20]. Only a limited number of variants, some-
times only one, successfully establish an infection in a
naïve host even though the transmitting partner harbors a
diverse range of viruses. Interestingly, we and others have
shown that HIV-1 infected injection drug users also often
harbor a relatively limited number of viruses early inl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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injection drug users compared to those who acquired the
virus through sexual contact [1-3]. Because greater initial
viral diversity is associated with faster disease progression
[17], it is possible that characteristics of the infecting qua-
sispecies are likely different among injection drug users
compared to individuals who acquire the virus through
sexual contact.
Diverse lines of evidence suggest that the observed
bottleneck during sexual transmission occurs as a con-
sequence of active selection rather than a stochastic
process. Infecting viruses are often more closely related
to HIV-1 variants found earlier during infection (termed
ancestral strains) as compared to those circulating near
the estimated time of transmission in the transmitting
partner, which suggests the preferential selection of
archived rather than contemporaneous strains during
transmission [5,20-23]. In agreement with this genotypic
observation, infecting viruses generally have smaller and
less glycosylated envelopes compared to the dominant
strains in the transmitting partner or variants isolated
during chronic infection [20,24]. Because viruses ex-
pand their envelope length and increase the number of
predicted glycosylation sites over the course of infection,
this argues that viruses with genotypes closer to ancestral
strains are favored for transmission [13,24-27]. The obser-
vation that newly infected subjects are predominantly
infected with viruses that use the CCR5 receptor (termed
R5) even though the transmitting partners often harbor
both R5 and variants that can only use the CXCR4 recep-
tor (termed X4) further suggests active selection during
transmission [5,8,11,12,14,20,21,28,29]. In addition, viruses
found during the chronic phase as compared to those
circulating early after acquisition have decreased sensitiv-
ity to CCR5 inhibitors, suggesting they have an enhanced
ability to use low levels of or structurally variant forms of
the CCR5 receptor [30-34]. Together, this implies that
chronic stage viruses that can only utilize the CXCR4
receptor or infect cells that have low levels or different
conformations of the CCR5 receptor are not favored for
transmission. Furthermore, recent studies demonstrate
both that T/F as compared to chronic infection strains
replicate to higher titers in the presence of IFN-α and
viruses become more susceptible to IFN-α within 1 year
after acquisition [11,35]. This implies that chronic stage
variants with decreased replication in the presence of
IFN-α have a disadvantage during transmission. In aggre-
gate, these findings strongly suggest that the transmitted
viruses with genotypic and phenotypic characteristics
similar to ancestral strains have preferential advantage
in establishing a systemic infection in a naïve host. It
remains unclear if similar active selection occurs among
viruses acquired through IDU as observed during sexual
acquisition. In this study, we compared properties of theenvelope quasispecies isolated from injection drug users
sampled prior to HIV-1 seroconversion to those present
over the first 2 to 3 years after acquisition.
Results
Subjects
We previously compared some characteristics among
the virus envelope swarm present within 1 year (early) to
those present around 2 – 3 years (chronic) after estimated
seroconversion [34]. We wished to compare more enve-
lope characteristics among these participants to unrelated
subjects who also reported IDU and who were sampled
prior to seroconversion (HIV RNA+/Ab-). None of the
subjects had received any anti-retroviral treatment.
Among the HIV RNA+/Ab- subjects, we chose to exam-
ine envelope quasispecies as opposed to the predicted T/F
strains because injection drug users have been shown to
acquire a greater number of variants [1-3]. As previously
argued [36], we presumed that the combination of virus
envelopes within a swarm would better recapitulate the
envelope phenotype of the infecting virus population.
Thus, we did not isolate presumed T/F strains from the
HIV RNA+/Ab- subjects. In addition, we did not select
specific envelopes from the early and chronic infection
samples because this selection would bias the study. As a
result, we used the same envelope isolation and virus
construction methodology among the HIV RNA+/Ab- as
used previously for the early and chronic infection group
[34]. We successfully amplified full-length envelopes from
8 of 10 cohort subjects retrospectively confirmed as sam-
pled prior to HIV-1 seroconversion. We could not amplify
envelopes from the remaining samples with various differ-
ent primer sets even though they contained relatively high
plasma virus levels (25,873 and 98,533 copies/ml). Inability
to amplify HIV-1 from some individuals even though they
contain high virus levels is similar to previous studies from
our group and others potentially suggesting sample prop-
erties prevents full-length envelope recovery [5,17,37].
Pooled amplification products from 4 independent PCRs
were placed within a NL4-3 backbone, and virus stocks
were generated using previous methods shown to recon-
stitute the viral quasispecies present in the original sample
[30,38,39]. Indeed in our previous study, we showed that
virus stocks contained similar level of genetic diversity
and types of envelope variants as that present in the
original sample [5]. Seven of the 8 envelope quasispe-
cies incorporated within NL4-3 yielded infectious virus
stocks. We compared the envelope characteristics from
these 7 HIV RNA+/Ab- subjects to those from 7 longitu-
dinally sampled individuals whose pool of amplified enve-
lopes incorporated into NL4-3 also yielded infectious
virus stocks (Table 1). All subjects, except A4 were hepa-
titis C virus (HCV) antibody positive prior to the time of
estimated HIV-1 seroconversion. This is a strong marker
Table 1 Subject characteristics
Subject Estimated PI (months)1 Plasma virus level CCR52 CXCR43 Tropism4
A31 Ab-/VL+ 154,381 12.7 13.83 R5/X4
A33 Ab-/VL+ 1,031,929 9.7 <0.03 R5
A38 Ab-/VL+ 31,174 10.8 <0.03 R5
A40 Ab-/VL+ 14,422 14.9 <0.03 R5
A41 Ab-/VL+ 1,289,549 13.3 <0.03 R5
A42 Ab-/VL+ 2,285,517 12.6 <0.03 R5
A43 Ab-/VL+ 499,713 12.3 <0.03 R5
A2 3.0 85,439 11.5 <0.03 R5
A4 5.0 2,158,680 1.9 14.3 R5/X4
A5 4.1 279,745 8.7 <0.03 R5
A17 4.9 40,634 14.6 <0.03 R5
A18 3.2 188,258 12.1 <0.03 R5
A23 4.9 56,189 10.6 <0.03 R5
A27 4.1 152,472 10.4 <0.03 R5
A2 21.4 30,996 19.1 <0.03 R5
A4 24.5 79,094 0.3 12.2 R5/X4
A5 27.2 137,661 11.1 <0.03 R5
A17 20.9 20,995 13.0 <0.03 R5
A18 27 12,299 11.6 <0.03 R5
A23 27.7 79,490 12.1 <0.03 R5
A27 27.1 17,668 9.8 11.91 R5/X4
1Interval in months from the estimated date of seroconversion to the day of sample collection. Ab-/VL+: Sampled prior to seroconversion.
2P24 (ug/ml) from U87/CD4/CCR5 cells at day 4 post-infection.
3P24 (ug/ml) from U87/CD4/CXCR4 cells at day 4 post-infection.
4Tropism as determined on U87/CD4+/CCR5 and U87/CD4+/CXCR4 cells.
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ported injecting drugs in the 6 months prior to estimated
HIV-1 seroconversion.
As expected, the HIV RNA+/Ab- (median log10 plasma
virus copies per ml 5.7, range 4.2 – 6.4) compared to the
chronic (median log10 4.5 copies/ml, range 4.1 – 5.1,
p =0.05) samples had higher plasma virus levels. Plasma
virus levels in the HIV-1 RNA+/Ab- as compared to the
early (median log10 5.2 copies/ml, range 4.6 – 6.3, p =0.6)
samples were not statistically different. Longitudinal
plasma virus levels significantly decreased from early
in disease to the chronic phase of infection (median log10
plasma virus copies per ml difference 0.4, range −0.1 – 1.4,
p =0.04). These plasma virus level differences followed the
expected pattern of high virus replication immediately
after acquisition and a decrease to a viral set point during
the chronic phase of disease.
Envelope sequences
Unlike previous studies of individuals presumably in-
fected through IDU, the primary goal of this study was
not to examine genotypic features of the HIV-1 enve-
lopes present at various times during infection [2,3].Even though bulk PCR cloning as compared to single
genome amplification (SGA) potentially introduces poly-
merase induced recombination artifacts, we examined 12
clonal sequences per sample because we compared overall
virus population characteristics rather than individual ge-
nomes [6,40]. Phlyogenetic analysis confirmed that all sub-
jects harbored subtype B HIV-1, and all early and chronic
infection sequences were related ruling out contamination
and HIV-1 superinfection (Figure 1). Envelopes from indi-
viduals sampled prior to seroconversion had lower genetic
diversity (median 0.001, range 0.0004 – 0.01) compared to
the chronic (median 0.007, range 0.001 – 0.02, p =0.05)
group, but there were non-significant differences com-
pared to envelopes from early (median 0.006, range
0.0008 – 0.008, p =0.2) infection. The HIV RNA+/Ab-
envelopes (median 0.001, range 0.0005 – 0.01) were also
less divergent than the chronic (median 0.007, range
0.001 – 0.02, p =0.05) and not statistically significantly
different compared to the early (median 0.004, range
0.0007 – 0.02, p =0.2) infection genotypes. Similar to
previous publications that examined HIV-1 subtype B
envelope genes by the bulk PCR cloning methodology,
the 3 groups did not have significant differences in
Figure 1 The HIV RNA+/Ab- envelopes are not related to the virologically linked early and chronic infection variants. Full-length HIV-1
envelope sequences were aligned with subtype reference sequences from the Los Alamos database using Clustal X. Maximum likelihood phylogenies
were generated using Paup with parameters from FindModel best fit evolutionary model as described previously [21]. Subject IDs are noted with the
different color nodes representing sequences from the 3 groups.
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aspargine linked glycosylation sites [24,27].
Replication competent viruses
Bulk PCR envelope products were incorporated into a
NL4-3 HIV-1 backbone to generate replication competent
recombinant viruses using previously described methods
[34]. Because we were interested in comparing the proper-
ties of the quasispecies at various times after infection, we
examined envelope pools as opposed to individual SGA
amplified envelopes. To confirm that potential polymerase
induced recombination during bulk PCR did not generate
novel phenotypes that did not exist in the original sample,
we compared virus stocks containing a pool of envelopes
generated using either SGA or bulk PCR. In 6 cases,
the virus stocks with the bulk PCR and SGA envelope
pools demonstrated equivalent infectivity and replication
kinetics (Additional file 1: Figure S1). This suggests that
the method for generating envelope pools did not have
a significant influence on their in-vitro phenotypic
properties.
Receptor usage
In-vitro, the majority of HIV RNA+/Ab-, early and
chronic infection envelopes used the CCR5 receptor and
failed to employ the CXCR4 co-receptor (Table 1). We
assessed sensitivity to receptor and fusion inhibitors as away to examine if the envelopes from the various stages
of infection had differences in their fusion capacity or
ability to use low levels of CD4 and CCR5. We have previ-
ously shown that these inhibitor sensitivity assays clearly
distinguish envelopes that require high versus low recep-
tor levels for host cell entry [30]. The HIV RNA+/Ab-
(median IC50 5.6, range 1.3 – 18.1 ug/ml) as compared to
the early (median IC50 3.8, range 2.9 – 8.9 ug/ml, p =0.5)
and chronic (median IC50 7.0, range 4.9 – 9.2 ug/ml,
p =0.6) envelopes showed no significant difference in
their sensitivity to a monoclonal anti-CD4 antibody
(Figure 2A). Paired analysis showed that the early as
compared to the chronic infection envelopes were mar-
ginally more sensitive to the monoclonal anti-CD4 anti-
body (median IC50 difference 2.5, range −0.3 – 6.3 ug/ml,
p =0.05).
CCR5 usage efficiency was assessed by estimating sen-
sitivity to the CCR5 inhibitor, Maraviroc. Envelopes
with documented ability to use the CXCR4 receptor were
omitted from this analysis. At the highest Maraviroc con-
centration tested (50 nM), all tested envelopes showed
greater than 95% inhibition suggesting there were no re-
sistant envelopes as observed in previous studies [33,41].
The HIV RNA+/Ab- envelopes (median IC50 3.2, range
0.8 – 6.3 nM) were more sensitive to Maraviroc compared
to the chronic (median IC50 4.5, range 4.3 – 8.4 nM,
p =0.03) but not early (median IC50 1.8, range 4.3 – 8.4 nM,
Figure 2 The HIV RNA+/Ab- envelopes have greater sensitivity to CCR5 and fusion inhibitors. Scatter plots show IC50s to CD4 antibody
(A), Maraviroc (B), and Enfuvirtide (C) with a line denoting the median. Each individual symbol represents a subject’s mean from a minimum of 3
independent experiments. Circles denote the estimates for the HIV RNA+/Ab- subjects. The longitudinal sampling is denoted by a unique symbol
(♦ A2, ■ A4, ○ A5, ★ A17, ▲ A18, ▼ A23, ●A27 ) for each subject. Symbols in gray denote virus stocks shown to be able to utilize the CXCR4
receptor. Significant differences (p ≤0.05) are indicated with a star in the graphs. Four envelope quasispecies with the documented ability to use
the CXCR4 receptor were omitted from the examination of Maraviroc sensitivity.
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showed a trend toward increased Maraviroc sensitivity
compared to the paired chronic infection variants (median
difference 2.7, range 1.7 – 7.6 nM, p =0.06). This suggests
that envelopes prior to seroconversion as compared to
those present at the chronic phase require higher CCR5
receptor levels for cell entry.
Sensitivity to Enfuvirtide was used to assess fusion
capacity. There was a trend that HIV RNA+/Ab- enve-
lopes (median 0.1, range 0.01 – 0.4 ug/ml) were more
sensitive compared to the chronic (median 0.3, range
0.03 – 0.5 ug/ml, p =0.07) but not the early variants
(median 0.07, range 0.006 – 0.2 ug/ml, p =0.9) (Figure 2C).
The early envelopes were significantly more sensitive
to Enfuvirtide compared to the longitudinally isolated
chronic variants (median difference 0.2, range 0.01 – 0.4
ug/ml, p =0.01). Similar to the Maraviroc findings, early
phase infection envelopes have the greatest susceptibility,
and pre-seroconversion as compared to the chronic phase
envelopes have higher Enfuviritide sensitivity.
Replication in primary cells
To assess replication, we monitored both p24 antigen
and infectious virus concentration as assessed on TZM-bl
cells in the culture supernatants post infection. The p24
antigen and infectious virus concentration curves over
time displayed similar morphology among the diverse
viruses. The area under the replication curve (AUC)
from the p24 antigen measurements was highly corre-
lated to the AUC from the infectious virus estimation
(ρ =0.7, p =0.002, Spearman rank correlation) suggesting
that either method could be used to follow virus produc-
tion (Additional file 1: Figure S2).
Replication in primary cell cultures was used to examine
if envelope quasispecies from different phases of infectionconfer varying replication capacity. Replication was exam-
ined in CD4+ T cells from 4 different individual donors.
There was large replication variation between the different
blood donor’s cells (Additional file 1: Figure S3). In
addition, a virus stock that produced the highest area
under the replication curve (AUC) in CD4+ T cells
from 1 donor did not always yield the highest AUC in
CD4+ T cells from other donors. Thus, different blood
donation volunteers CD4+ T cells supported replication to
varying levels in both individual virus stocks and among
the entire group. As a result, we chose to analyze replica-
tion both individually in primary cells from 1 donor and
in aggregate among primary cells from different donors.
In cells from a majority of donors, the HIV RNA+/Ab- en-
velope viruses replicated to greater extent compared to
the viruses with early and chronic infection envelopes, but
these differences were not statistically significant in any of
the donors individually (Figure 3). In aggregate, the HIV
RNA+/Ab- envelopes also did not have statistically sig-
nificant replication difference compared to the early
(log estimated AUC difference 0.6, 95% confidence inter-
val (CI) -0.1 – 1.3, p =0.07) or chronic (log AUC difference
0.1, 95% CI −0.7 – 0.8, p =0.7) group. The early infection
envelope viruses did not have significantly different repli-
cation AUC compared to the chronic infection envelope
variants in the CD4+ T cells, both in aggregate (log AUC
difference 0.3, 95% CI −1.1 – 1.6, p =0.6) or when the cells
from different donors were analyzed separately.
Dendritic cells (DCs) have been proposed to play an
important role in HIV-1 transmission because they can
efficiently capture viruses and transmit them to CD4+ T
cells, which significantly enhances virus replication [42-44].
We examined if the envelope quasispecies from differ-
ent phases of infection confer differences in ability to
utilize monocyte derived DCs (MDDCs). Again, donor
Figure 3 Viruses with envelopes from different phases of infection demonstrate similar replication capacity in CD4+ T cells. Scatter
plots show replication area under the curve (AUC) in activated CD4+ T cells from 4 different HIV-1 seronegative donors (A-D). The AUC was
calculated over 10 days post infection. Each individual symbol represents a subject’s AUC. Similar to Figure 2, in the early and chronic group
unique symbols are used to show the longitudinal changes within an injection drug user. In each scatterplot, the lines denote the median.
Symbols in gray denote virus stocks shown to be able to utilize the CXCR4 receptor.
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ent donors (Additional file 1: Figures S4 and S5). In 1
donor’s mature MDDCs – CD4+ T cell co-culture, the
HIV RNA+/Ab- replicated less efficiently as compared
to the chronic viruses (Figure 4). In aggregate, the HIV
RNA+/Ab- envelope viruses had significantly lower
replication AUC compared to the chronic (log AUC
difference −1.3, 95% CI −2.6 – 0.002, p =0.03) but non-
significant differences compared to the early (log AUC
difference −0.7, 95% CI −2.1 – 0.6, p =0.3) infection en-
velopes in mature MDDC – CD4+ T cell co-cultures.
There was, however, no statistical trend or significant
difference among the early versus chronic envelopes
(log AUC difference 1.5, 95% CI −1.3 – 4.2, p =0.3).
The HIV RNA+/Ab- envelopes also showed lower
replication AUC compared to the early (log AUC dif-
ference −1.0, 95% CI −2.3 – 0.3, p =0.1) and chronic
variants (log AUC difference −0.4, 95% CI −1.5 – 0.9,
p =0.6) in immature MDDC – CD4+ T cell co-cultures,
but the differences were not statistically significant. In
aggregate, the early as compared to the chronic infec-
tion envelope viruses also did not have significant rep-
lication differences in immature MDDC – CD4+ T cell
cocultures (log AUC difference −3.1, 95% CI −7.3 – 0.7,
p =0.1).Gut homing receptor usage
Early after HIV-1 acquisition, high level virus replication
occurs in gut associated lymphoid tissue (GALT) [45].
The gut homing receptor, α4β7, potentially facilitates
virus migration from the site of acquisition to the GALT
[46-48]. In our previous studies, we showed binding and
replication augmentation in cells with increased as com-
pared to normal α4β7 expression among viruses with
known α4β7 reactivity, such as HIV-1SF162 and HIV-1Bal
[49]. In addition, previous studies from our group and
others have shown that α4β7 inhibitors often fail to pre-
vent virus replication in and binding to cells expressing
high levels of α4β7 [12,49]. Thus, we used similar methods
to examine if envelope quasispecies from the 3 phases
of infection had replication and binding differences in
retinoic acid (RA) stimulated CD4+ and CD8+ T cells
with flow cytometry confirmed high levels of α4β7
receptor respectively in the absence of any inhibitors.
The HIV RNA+/Ab- envelopes showed no significant
replication difference compared to the early (log RLU
difference −0.5, 95% CI −1.3 – 0.2, p =0.1) or chronic
(log RLU difference 0.3, 95% CI −0.6 – 1.2, p =0.5) enve-
lopes in α4β7 high CD4+ T cells (Figure 5A – D). In
addition, replication was not significantly different in
the α4β7 high CD4+ T cells in any of the 4 donors when
Figure 4 Viruses with HIV RNA+/Ab- compared to chronic envelopes have lower replication in mature MDDC – CD4+ T cells. Similar to
Figure 3, scatter plots show replication area under the curve in mature (A – D) and immature (E – H) MDDC – CD4+ T cell co-cultures from 4 dif-
ferent HIV-1 seronegative donors. Similar to Figure 2, in the early and chronic group unique symbols are used to show the longitudinal changes
within an injection drug user. In each scatterplot, the lines denote the median. Significant differences (p ≤0.05) are indicated with a star in the
graphs. Symbols in gray denote virus stocks shown to be able to utilize the CXCR4 receptor.
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early as compared to the chronic infection envelope vi-
ruses also did not have significant replication differences
in α4β7 high CD4+ T cells (log RLU difference 1.0, 95%
CI −0.2 – 2.8, p =0.4).
The HIV RNA+/Ab- as compared to the chronic enve-
lope viruses showed significantly greater binding to α4β7
high CD8+ T cells in 1 of the 4 donors (Figure 5E - H).Figure 5 Viruses with envelopes from different phases of infection de
plots show relative light units in TZM-bl cells infected with 50 ul of virus su
CD4+ T cells (A – D). Each symbol represents mean of 3 independent RLU
from virus exposed FACS confirmed α4β7 high CD8+ T cells from 4 differe
2 independent RNA copy quantifications. Similar to Figure 2, in the early an
changes within an injection drug user. In each scatterplot, the lines denote
in the graphs. Symbols in gray denote virus stocks shown to be able to utiIn aggregate, the HIV RNA+/Ab- envelopes also showed
significantly greater binding compared to the chronic
(log RNA copy difference 1.0, 95% CI 0.02 – 1.9, p =0.03)
but not the early (log RNA copy difference 0.3, 95%
CI −0.3 – 1.0, p =0.3) envelopes. The early as com-
pared to the chronic infection envelope viruses did not
have significant binding differences to α4β7 high CD8+ T
cells (log RNA copy difference 0.6, 95% CI −0.01 – 0.6,monstrate similar replication in α4β7 high CD4+ T cells. Scatter
pernatants recovered from virus exposed FACS confirmed α4β7 high
measurements. Scatter plots show number of RNA copies recovered
nt HIV-1 seronegative donors (E - H). Each symbol represents mean of
d chronic group unique symbols are used to show the longitudinal
the median. Significant differences (p ≤0.05) are indicated with a star
lize the CXCR4 receptor.
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1 donor’s cells.
Susceptibility to IFN-α
In the SIV/macaque model, it has been shown that
exposure to virus elicits a strong anti-viral response,
such as elevated levels of IFN-α [50]. These anti-viral
responses induce target cells, such as activated CD4+
T cells, to the site of invasion and also inhibit virus
replication. Recent studies suggest that HIV-1 variants
able to replicate in the presence of high interferon
levels are potentially favored to establish an infection
in a naïve host [11,35]. We examined if the virus stocks
with HIV RNA+/Ab- envelope quasispecies demon-
strated greater IFN-α resistance compared to the early
and chronic infection envelope viruses (Additional file 1:
Figure S6). Surprisingly, the HIV RNA+/Ab- envelope vi-
ruses demonstrated significantly lower resistance com-
pared to the chronic group in CD4+ T cells from 2 of the
4 donors (Figure 6). In aggregate, the HIV RNA+/Ab- en-
velope viruses had a statistically significant 0.7 log lower %
IFN-α resistance compared to the chronic group (95%
CI −1.23 – -0.15, p =0.008). There was also a statisticalFigure 6 The HIV RNA+/Ab- compared to the chronic envelopes have
resistance (replication in the presence as compared to the absence of IFN-
Similar to Figure 2, in the early and chronic group unique symbols are use
each scatterplot, the lines denote the median. Significant differences (p ≤0
virus stocks shown to be able to utilize the CXCR4 receptor.trend that the HIV RNA+/Ab- envelopes were more
IFN-α sensitive compared to the early group (log % IFN
resistance difference −0.51, 95% CI −0.6 – 1.2, p =0.08).
In aggregate, the early as compared to chronic infection
envelope viruses showed a trend towards greater IFN-α
sensitivity (log %IFN-α resistance difference −0.51, 95%
CI −1.14 – 0.12, p =0.1). This suggests that in injection
drug users IFN-α resistance increases from the pre-
seroconversion to the early and eventually to the chronic
phase of infection.
Discussion
Even though IDU is a relatively common route for HIV-1
acquisition, there has been limited understanding about
the pathogenesis associated with this mode of transmis-
sion. In contrast to mucosal acquisition, viruses acquired
through IDU do not encounter an epithelial barrier in
accessing potential target cells, suggesting that the charac-
teristics of the acquired variants may be different among
mucosal versus non-mucosal acquisition. Indeed, previous
studies have suggested that injection drug users are often
infected with more variants compared to individuals that
acquire the virus through heterosexual or homosexualgreater sensitivity to interferon-α. Scatter plots show % interferon
α) in CD4+ T cells from 4 different HIV-1 seronegative donors (A – D).
d to show the longitudinal changes within an injection drug user. In
.05) are indicated with a star in the graphs. Symbols in gray denote
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phenotypic characteristics of the virus envelope quasispe-
cies isolated prior to seroconversion, within an estimated
1 year after acquisition, and during the chronic phase
of disease among individuals that presumably acquired
HIV-1 through IDU. We found that the envelope quasis-
pecies in HIV RNA+/Ab- compared to the chronically
infected subjects were significantly more sensitive to a
CCR5 inhibitor and IFN-α, and had a trend towards in-
creased susceptibility to Enfuvirtide. Interestingly, the
early as compared to the chronic infection envelope qua-
sispecies displayed either a statistical trend or significantly
greater sensitivity to Maraviroc, Enfuvirtide, and IFN-α.
This suggests that injection drug users prior to serocon-
version possess unique HIV-1 envelope quasispecies that
require high CCR5 receptor levels for host cell entry, have
lower fusion capacity, and confer enhanced sensitivity to
IFN-α. Over the first 2 to 3 years of infection, virus enve-
lope quasispecies evolve the ability to use lower CCR5
levels, have enhanced fusion capacity, and confer de-
creased IFN-α sensitivity. In aggregate, our findings sug-
gest that viruses with unique envelope characteristics
preferentially establish a systemic infection among injec-
tion drug users.
Previous studies from our group and others show that
the genetic bottleneck during IDU transmission is not as
restrictive because the likelihood of acquiring more than
a single virus appears higher compared to other routes
of HIV-1 acquisition, such as sexual contact [1-3]. Even
though the genetic bottleneck is not as restrictive com-
pared to acquisition across a mucosal barrier, the number
of infecting variants is still less than what would be typic-
ally present in an individual sampled during the early and
chronic phases of disease [51]. Smaller number of variants
than expected may be circulating in newly infected in-
jection drug users because the virus could be acquired
from another individual in the acute phase of infection
with relatively limited viral genetic diversity. On the
other hand, contaminated needles may only harbor a
small number of infectious virions. Because it is logistic-
ally difficult to sample the transmission source, it remains
unclear if the relatively limited number of variants ob-
served in injection drug users early after acquisition is due
to active selection or limited source diversity.
We and others have previously shown that mucosally
acquired viruses sampled early after acquisition, including
T/F viruses, have decreased ability to use low levels of or
different conformation of the CCR5 receptor compared to
unrelated chronic controls [30,31,33]. In this study, we
also observed that swarm present prior to seroconversion
showed greater sensitivity to Maraviroc compared to
the swarm sampled during the chronic phase of disease.
Because CCR5 sensitivity is directly correlated to fusion
inhibitor susceptibility [52], we also found that the HIVRNA+/Ab- envelope variants showed a trend toward
greater sensitivity to Enfuvirtide compared to the chronic
strains [30,52,53]. In aggregate, pre-seroconversion vari-
ants present in injection drug users and mucosally ac-
quired strains require high levels of CCR5 in an invariant
structure to enter host cells. This potentially suggests that
similar biological mechanisms favor the ability of relatively
CCR5 receptor and fusion inhibitor sensitive variants in
establishing a disseminated infection regardless of whether
the virus is acquired through IDU or across a mucosal
barrier.
Interestingly, we found that envelopes isolated prior to
seroconversion conferred greater sensitivity to IFN-α
compared to the chronic stage envelopes. Two previous
investigations have shown that full-length T/F and acute
stage viruses are relatively interferon resistant [11,35].
This has been used to argue that viruses able to replicate
in the presence of high interferon levels at the site of inva-
sion preferentially establish a systemic infection leading to
the observed genetic bottleneck during transmission.
Interferon resistance may not lead to a genetic restric-
tion in injection drug users because IDU is potentially
associated with persistent inflammation [54,55]. Thus,
when a naïve individual acquires HIV-1 from a chronic-
ally infected injection drug user interferon susceptibility
will not present a barrier for most variants in establish-
ing a new systemic infection because viruses circulating
in the transmitter may already be relatively interferon
resistant. Indeed, a previous study failed to show inter-
feron susceptibility difference between sexually acquired
subtype C T/F versus chronic phase variants presumably
because the chronically infected transmitters have persist-
ent inflammation [11]. In addition, while the observed
differences were statistically significant, it remains unclear
if they are clinically meaningful because, in aggregate, the
chronic infection viruses were around 2 fold more resist-
ant to interferon compared to the HIV RNA+/Ab- enve-
lope variants. On the other hand, we may have failed to
replicate the previous findings because our studies only
examined envelope differences, and non-envelope portions
of the virus genome may be the genetic determinant for
interferon resistance [56].
We also found that the HIV RNA+/Ab- as compared
to the chronic envelope viruses replicated less efficiently
in mature MDDC – CD4+ T cells. This corroborates
other published findings showing that chronic infection
envelope quasispecies compared to unrelated sexually
acquired T/F envelopes demonstrated higher replication
in MDDC – CD4+ T cell co-cultures [39]. Furthermore,
in our previous study, we found that viruses with enve-
lopes from chronically infected individuals replicated to
greater extent in mature MDDC – CD4+ T cells com-
pared to the variants with envelopes from the newly in-
fected heterosexual partner [5]. It should be noted that
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chronic infection controls have greater replication in
MDDC – CD4+ T cell co-cultures although significant
differences were only observed in subtype B and not
subtype C HIV-1, and the results were based on infections
in primary cells from only two different donors [11]. In
summary, these results suggest that if dendritic cells play a
potential role during initial HIV-1 acquisition then the en-
velope glycoprotein does not solely dictate which variants
successfully establish a new infection.
Our findings failed to reveal replication differences in
any of the other primary cells among viruses sampled
during the various phases of disease. Even though, HIV
RNA+/Ab- as compared to the chronic envelopes dem-
onstrated significantly greater binding to α4β7 high
CD8+ T cells, importantly, there was no significant
replication difference in the α4β7 high CD4+ T cells.
Replication as opposed to binding is likely the more
important phenotype that determines a virus’ fitness
for establishing a new infection in a naïve individual.
Our previous study of recipient transmitter pairs showed
that envelope variants circulating in the chronically in-
fected sexual partner compared to those present in the
newly infected subject had higher replication in CD4+ T
cells with high or normal levels of α4β7 levels and with
and without MDDCs [5]. In contrast, however, another
study showed full length sexually acquired T/F strains had
greater MDDC binding and trans infection compared to
unrelated chronic infection controls [11]. There are likely
a number of reasons we may have failed to observe rep-
lication differences in the other primary cells among the
3 groups in our study. Even though we detected some
significant phenotypic differences, it is likely that we were
statistically underpowered to detect small variations
because we only examined 7 subjects in each group.
Previous studies using relatively similar number of
samples per group (n =6 to 11) showed significant differ-
ences in sensitivity to receptor inhibitors and replication
kinetics among sexually acquired envelope variants com-
pared to the unrelated chronic infection strains or variants
circulating in the transmitting partner [5,14,39,57]. Be-
cause selection bottleneck is less restrictive during IDU
compared to mucosal acquisition, it can be hypothesized
that potential differences among the variants at various
times post acquisition are likely smaller. Thus, larger
sample sizes would be needed to document a significant
difference. Although we obtained our samples from one
of the largest cohorts of injection drug users [58], there
are still only a limited number of samples from individ-
uals sampled prior to HIV-1 seroconversion. We did not
seek samples from other cohort of injection drug users
because of subject heterogeneity and viral subtype dif-
ferences [59,60]. In context to the statistical analyses, it
should be noted that we did not adjust for multiplecomparisons. Clearly conservative adjustments for multiple
comparisons would have rendered all findings statistically
insignificant given the small sample sizes. Regardless, the
observed significant differences are unlikely due random
chance alone because of the similarity in the observed
unique phenotypic characteristics among the earliest vari-
ants sampled from both sexually and IDU acquired viruses.
Another reason we may have failed to observe replica-
tion differences among the groups in our study is because
we compared the envelope variants isolated prior to sero-
conversion to viruses sampled later in infection from un-
related subjects [5]. The limited variants that establish a
systemic infection in a naïve host may harbor a phenotype
that favors its acquisition compared to the swarm present
in the transmission source. This selection property, how-
ever, may not necessarily be significantly different among
the acquired variants and unrelated chronic infection
controls. It should be noted, however, that we examined
envelope properties in the context of an infectious clone,
which is different from most studies that use 293T derived
single cycle virus pseudotypes [12,14,28,57]. Besides the
fact that single cycle viruses cannot be used to examine
replication in primary cells, 293T as compared to periph-
eral blood mononuclear cell (PBMC) derived viruses often
have different envelope density and glycans, which can
influence receptor binding, neutralization and other prop-
erties [47,61,62]. Thus, peripheral blood mononuclear cell
(PBMC) generated viruses have more physiologically
relevant phenotypes compared to the 293T transfection
derived virions. Although, it cannot be unequivocally
stated that PBMC passage does not affect the virus
phenotype, changes are generally less likely to occur in
the short term cultures (maximum 7 days) used in our
study. In addition, because all virus stocks were generated
in a similar manner, changes induced by the short term
PBMC passage should have affected the viruses from the 3
different phases of infection in an equivalent manner.
There are a number of limitations with our study.
First, similar to all investigations of injection drug users,
one can never be certain that the subjects acquired their
infection through IDU. Even though individuals may
report active IDU and have strong markers for this ac-
tivity, such as co-infection with HCV, there is no way
to definitively exclude the possibility that they acquired
their virus through sexual contact. Second, we only
examined properties of the envelope glycoprotein qua-
sispecies. It is quite possible that other viral genomic
regions, such as gag, influence replication especially in
MDDC – CD4+ T cell co-cultures [63,64]. Third, we did
not isolate the T/F envelopes from the HIV RNA+/Ab-
subjects. Although HIV-1 diversifies relatively quickly,
there were likely minimal changes in the quasispecies
isolated prior to seroconversion as opposed to the pre-
dicted T/F strains. In aggregate, from our studies, we
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compared to chronic phase infection virus envelope
quasispecies when inserted into an isogenic backbone
require higher CCR5 receptor levels, have lower fusion
capacity, replicate less efficiently in MDDC-CD4+ T cell
co-cultures, and confer enhanced IFN-α sensitivity.
Conclusion
To our knowledge, this is the first study that has exten-
sively examined the envelope phenotypic properties of
HIV-1 variants found among individuals who presumably
acquired their infection through IDU. A strength of this
study is that we sampled subjects prior to seroconversion,
and thus we were able to characterize the earliest virus
swarm after acquisition, albeit not the predicted T/F vari-
ants. While previous genotypic studies suggest that limited
number of variants, although likely greater than the num-
ber acquired across mucosal surfaces, establish a systemic
infection in injection drug users, our phenotypic data
suggest that these earliest envelopes have unique enve-
lope properties compared to chronic infection variants.
Phenotypic similarities among mucosally and IDU ac-
quired viruses, such as a requirement for high CCR5
receptor levels, suggest that the different modes of
acquisition share similar biological mechanisms that
dictate the types of variants that establish a systemic
infection in a naïve individual.
Methods
Subjects
All subjects examined were from the AIDS Linked to
the IntraVenous Experience (ALIVE) cohort, which fol-
lows HIV-1 uninfected and HIV-1 infected injection
drug users in Baltimore, Maryland through semiannual
visits [58]. Estimated acquisition interval was based on
serological testing of longitudinal samples. Newly sero-
positive subjects’ previously seronegative sample was
tested for HIV-1 RNA with a pooled viral load assay as
previously described to identify the HIV-1+/Ab- indi-
viduals [65,66]. The seroconversion date was estimated
as the midpoint between the last HIV-1 seronegative
visit and the day the first HIV-1 seropositive sample
was obtained. All subjects sampled within a year (early)
and around two to three after seroconversion (chronic)
have been described previously [34]. The study was ap-
proved by human subjects review boards at Johns Hopkins
University, Bloomberg School of Public Health, and
Brigham and Women’s Hospital; all participants pro-
vided informed written consent.
Envelope amplification and analysis
For all subjects, HIV-1 RNA was isolated from around
100 ul of the serum samples, and RT-PCR was used to
amplify a library of full-length envelope genes usingpreviously described primers and amplification conditions
[6]. For each subject, a minimum of 4 independent PCRs
were pooled to generate a library of envelopes from
each serum sample. Pooled envelope amplifications
were inserted into linearized pCMV-NL4-3-PBS→
LTRΔGp160 plasmid using yeast gap-repair homologous
recombination as previously described [34,38]. Clone
pools were transfected into HEK293T cells and culture
supernatants were passaged on PBMC for a maximum
of 7 days. In contrast to our previous study [34], all virus
stocks were generated from a combination of superna-
tants obtained from 3 independent cloning attempts
from 3 different PBMC cultures. The number of infec-
tious particles (IP) was estimated on TZM-bl cells as
previously described [25,67].
Twelve individual full-length envelopes were isolated
and sequenced from each subject’s clones. All unique se-
quences reported in this publication have been submitted
to Genbank (accession numbers KP171242 - KP171495).
Average of pairwise distances was used to estimate genetic
diversity. Divergence was estimated as the average dis-
tance from the subject’s sequences to the estimated ances-
tor as described previously [21]. Amino acid lengths and
number of predicted N-linked glycosylation sites (PNGS)
of different envelope segments were analyzed as previ-
ously described [21].
Inhibitor sensitivity
TZM-bl, U87/CD4/CXCR4 and U87/CD4/CCR5 cells,
Enfuvirtide, Maraviroc, and CD4 B4 monoclonal antibody
were obtained through Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH [68-70]. Infec-
tion of TZM-bl cells in the absence and presence of two-
fold serial dilution of the inhibitor was used to estimate
the 50% inhibitory concentration (IC50) as previously de-
scribed [30]. All reported IC50s are mean estimates from a
minimum of 3 independent assays. Coreceptor usage was
determined by monitoring p24 production in U87/CD4/
CXCR4 and U87/CD4/CCR5 cells infected with 500 IP of
each virus supernatant.
Primary cells and infections
PBMCs were isolated from HIV-1 negative blood dona-
tion volunteer’s buffy coats using Ficoll Hypaque density
centrifugation. Monocytes were isolated from PBMCs
using the percoll gradient method [71]. Primary human
immature DCs were derived from monocytes, as described
previously [72]. Briefly, monocytes were cultured in
RPMI/10% FBS containing recombinant human GM-CSF
(0.5 μg/ml; Leukine, Berlex) and recombinant human
IL-4, 100 U/ml (Peprotech) for 6 days. Mature DCs
were obtained by culturing immature DCs at day six of cul-
ture for two additional days in the presence of 100 ng/ml of
ultra-pure E. coli LPS (Sigma). Primary human CD4+ and
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pleted PBMCs using antibody conjugated magnetic beads
(Miltenyi Biotech) according to manufacturer’s instructions.
CD4+ T cells were activated with 2% phytohaemagglutinin
(PHA) and 20 ug/ml recombinant human IL-2 (r-IL-2) for
2 days.
Around 2 × 106 CD4+ T cells were exposed to 1,000
infectious particles in the presence of 20 U/ml diethyla-
minoethyl (DEAE) Dextran. After two hours, cultures
were washed a minimum of three times to remove un-
bound virus. Around 0.5 × 106 immature or mature DCs
were independently exposed to 1,000 infectious particles.
After three hours, DC cultures were washed a minimum
of three times to remove unbound virus. Virus exposed
DC infections were cultured either with or without au-
tologous activated CD4+ T cells. Infectious virus concen-
tration was estimated by infecting 1 × 104 TZM-bl cells
with 4 to 8 serial two-fold dilutions of supernatant culture
starting at 50 ul (Additional file 1: Figures S6 and S7 for
representative examples). All infections were done in
triplicate in a 96 well format. Two days post-infection,
TZM-bls were examined for beta-galactosidase produc-
tion using Galacto-Light Plus System (Applied Biosys-
tems). Virus stock dilutions in the non-linear range of
the TZM-bl assay were discarded. A linear interpo-
lated curve of the relative light units (RLUs) versus
supernatant dilution was used to estimate RLU/ul. The
AUC was generated from the plot of RLU/ul versus days
post infection. Primary cell infections were repeated a
minimum of 4 times with cells from 4 different buffy
coats. Culture supernatants were also assessed for p24
antigen content using an in house assay as previously
described [73].
Replication in CD4+ and binding to CD8+ T cells
expressing high α4β7 integrin levels
Gut homing receptor, α4β7, usage was examined as pre-
viously described [49]. Briefly, both CD8+ and CD4+ T
cells were activated with PHA, r-IL-2, and retinoic acid
(RA) for 6 days. Only cells confirmed to have enhanced
α4β7 expression as determined by binding of phycoeryth-
rin (PE) conjugated anti-mouse integrin β7 antibody
(clone FIB27) (BioLegend) were used in the subsequent
assays. Around 1 × 106 CD8+ and CD4+ T cells were
exposed to 1 × 105 infectious virus for 1 hour at 4°C in
HEPES-buffered saline with 100 μM CaCl2 and 1 mM
MnCl2. Cells were washed a minimum of 3 times to re-
move unbound virus. RNA was isolated from the CD8+
T cells using the QIAAMP Viral RNA kit (QIAGEN).
HIV-1 copies were quantified using quantitative RT-PCR
using previously described methods [74,75]. The CD4+ T
cells were incubated at 37°C 5% CO2, and the infectious
virus concentration in the culture supernatants was mea-
sured after 3 days as detailed above.Replication in the presence of IFN-α
CD4+ T cells were pre-treated with 1000 U/ml IFN-2α
(PBL Assay Science) for 4 hours. Around 2 × 105
pre-treated and untreated CD4+ T cells were exposed
to 2 × 103 infectious virus for 2 – 3 hours. Following
exposure, cells were washed and re-plated in the presence
or absence of IFN-α along with 20 U/ml r-IL-2. After
7 days, supernatants were removed, and TZM-bl cells
were exposed to 4 different supernatant dilutions. Im-
portantly, we confirmed that TZM-bl infections were
not affected by the presence of IFN-α (Additional file 1:
Figure S7). The RLUs generated from the TZM-bl infec-
tions were measured 2 days after exposure, and the RLU
versus supernatant dilution plot was used to estimate an
AUC for each virus in the presence and absence of IFN-α.
The % IFN-α resistance was estimated from the ratio of
AUC in the presence compared to the absence of IFN-α.
Statistical analysis
Summary characteristics were compared among the HIV
RNA+/Ab- envelopes to the other group of viruses using
the Wilcoxon rank-sum test. Longitudinal comparisons
among the early and chronic samples were done using
the matched pair Wilcoxon rank-sum test. All p-values
were based on a two-sided test. Initially, comparisons
were done independently for primary cells obtained from
different donors. Linear regression models were used for
the aggregate comparisons among the three groups in
the primary cells from four different donors. The differ-
ences between chronic and early values were the outcome
for the longitudinal analysis. Linear regressions models of
the log transformed values were adjusted for the four
different donors and considered an interaction between
the three groups and the origin of the primary cells. The
correlation between observations from the same donor
was negligible, and adjusting for this via generalized es-
timating equations (GEE) had no impact on the results.
Nonparametric bootstrapping with 1999 bootstrapped
samples was used to obtain 95% confidence intervals.
All statistical analyses were done with either Intercooled
Stata version 8.0 (Stata Corporation, College Station, TX)
or R 2.15 (r-project.org).
Additional file
Additional file 1: Figure S1. Infectivity (I) and replication kinetics are
not significantly different among recombinant viruses with envelopes
amplified using either single genome amplification (SGA) or multiple bulk
PCR. Figure S2. Virus replication kinetics are similar as measured by the
detection of p24 and infectious virus on TZM-bl cells. Figure S3. Virus
replication varies in CD4+ T cells from different donor. Figure S4. Virus
replication varies in mature MDDC - CD4+ T co-cultures with cells from
different donors. Figure S5. Virus replication varies in immature
MDDC - CD4+ T co-cultures with cells from different donors. Figure S6.
Virus replication in the presence or absence of IFN-α in CD4+ T cells from
different donors.
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